Revathy Sampath-Kumar, Ori Ben-Yehuda, Belal Al Khiami, Lawrence Ang, Anna Melendez, Ryan Reeves, Ehtisham Mahmud
{"title":"手术性ACT峰值与股骨PCI术后全因死亡率相关。","authors":"Revathy Sampath-Kumar, Ori Ben-Yehuda, Belal Al Khiami, Lawrence Ang, Anna Melendez, Ryan Reeves, Ehtisham Mahmud","doi":"10.1016/j.jscai.2024.102387","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A minimum threshold activated clotting time (ACT) to guide heparin dosing during percutaneous coronary intervention (PCI) is associated with lower ischemic complications. However, data are variable regarding the risk of high ACT levels. The aim of this study was to assess the impact of peak procedural ACT on complications and mortality for transfemoral and transradial access PCI.</p><p><strong>Methods: </strong>The UC San Diego Health National Cardiovascular Data Registry CathPCI Registry was used to obtain data on patients who underwent native vessel PCI from January 2007 to September 2022. Coronary artery bypass graft patients and those who received bivalirudin were excluded. Complications and all-cause mortality at 30 days and 1-year post-PCI were assessed by ACT tertile.</p><p><strong>Results: </strong>A total of 2473 patients (age 65 ± 12 years; 74% male) undergoing PCI with 53% femoral and 47% radial access were included. The majority (82%) had 1-vessel coronary artery disease with heterogeneous clinical presentations (21.8% ST-elevation myocardial infarction, 25.4% non-ST-elevation myocardial infarction, 4.9% unstable angina, 33.8% stable angina, 3.4% atypical chest pain, 10.7% other indication for PCI). With femoral access, patients in the third tertile (ACT ≥ 275) had significantly higher all-cause mortality at 30 days (5.3% vs 2.7% vs 0.9%; <i>P</i> < .001), 6 months (6.3% vs 4.0% vs 2.0%; <i>P</i> = .007), and 1 year (9.0% vs 6.0% vs 2.7%; <i>P</i> < .001) compared to the second (ACT 228-275) and first tertile (ACT ≤ 228), respectively. A 30-day landmark analysis revealed that there was no difference in all-cause mortality beyond 30 days (3.9% vs 3.4% vs 1.8%; <i>P</i> = .176). There were increased bleeding complications in the highest tertile (12.8% vs 9.8% vs 7.5%; <i>P</i> = .034) and a higher need for blood products (10.4% vs 6.7% vs 5.4%; <i>P</i> = .014). There was no difference in ischemic major adverse cardiovascular events specifically periprocedural myocardial infarction or stroke between tertiles. There was no difference in clinical outcomes by peak ACT for patients who had radial access.</p><p><strong>Conclusions: </strong>Higher ACT with transfemoral access PCI was associated with increased 30-day mortality, bleeding complications, and need for blood products post-PCI.</p>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"3 12","pages":"102387"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725081/pdf/","citationCount":"0","resultStr":"{\"title\":\"Peak Procedural ACT Is Associated With All-Cause Mortality After Femoral Access PCI.\",\"authors\":\"Revathy Sampath-Kumar, Ori Ben-Yehuda, Belal Al Khiami, Lawrence Ang, Anna Melendez, Ryan Reeves, Ehtisham Mahmud\",\"doi\":\"10.1016/j.jscai.2024.102387\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A minimum threshold activated clotting time (ACT) to guide heparin dosing during percutaneous coronary intervention (PCI) is associated with lower ischemic complications. However, data are variable regarding the risk of high ACT levels. The aim of this study was to assess the impact of peak procedural ACT on complications and mortality for transfemoral and transradial access PCI.</p><p><strong>Methods: </strong>The UC San Diego Health National Cardiovascular Data Registry CathPCI Registry was used to obtain data on patients who underwent native vessel PCI from January 2007 to September 2022. Coronary artery bypass graft patients and those who received bivalirudin were excluded. Complications and all-cause mortality at 30 days and 1-year post-PCI were assessed by ACT tertile.</p><p><strong>Results: </strong>A total of 2473 patients (age 65 ± 12 years; 74% male) undergoing PCI with 53% femoral and 47% radial access were included. The majority (82%) had 1-vessel coronary artery disease with heterogeneous clinical presentations (21.8% ST-elevation myocardial infarction, 25.4% non-ST-elevation myocardial infarction, 4.9% unstable angina, 33.8% stable angina, 3.4% atypical chest pain, 10.7% other indication for PCI). With femoral access, patients in the third tertile (ACT ≥ 275) had significantly higher all-cause mortality at 30 days (5.3% vs 2.7% vs 0.9%; <i>P</i> < .001), 6 months (6.3% vs 4.0% vs 2.0%; <i>P</i> = .007), and 1 year (9.0% vs 6.0% vs 2.7%; <i>P</i> < .001) compared to the second (ACT 228-275) and first tertile (ACT ≤ 228), respectively. A 30-day landmark analysis revealed that there was no difference in all-cause mortality beyond 30 days (3.9% vs 3.4% vs 1.8%; <i>P</i> = .176). There were increased bleeding complications in the highest tertile (12.8% vs 9.8% vs 7.5%; <i>P</i> = .034) and a higher need for blood products (10.4% vs 6.7% vs 5.4%; <i>P</i> = .014). There was no difference in ischemic major adverse cardiovascular events specifically periprocedural myocardial infarction or stroke between tertiles. There was no difference in clinical outcomes by peak ACT for patients who had radial access.</p><p><strong>Conclusions: </strong>Higher ACT with transfemoral access PCI was associated with increased 30-day mortality, bleeding complications, and need for blood products post-PCI.</p>\",\"PeriodicalId\":73990,\"journal\":{\"name\":\"Journal of the Society for Cardiovascular Angiography & Interventions\",\"volume\":\"3 12\",\"pages\":\"102387\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725081/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Society for Cardiovascular Angiography & Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jscai.2024.102387\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Society for Cardiovascular Angiography & Interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jscai.2024.102387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:在经皮冠状动脉介入治疗(PCI)中,指导肝素剂量的最小阈值激活凝血时间(ACT)与较低的缺血性并发症相关。然而,关于高ACT水平风险的数据是可变的。本研究的目的是评估程序性ACT峰值对经股动脉和经桡动脉PCI手术并发症和死亡率的影响。方法:使用加州大学圣地亚哥分校健康国家心血管数据登记处(CathPCI登记处)获取2007年1月至2022年9月接受原生血管PCI治疗的患者的数据。排除冠状动脉旁路移植术患者和接受比伐鲁定治疗的患者。采用ACT方法评估pci术后30天和1年的并发症和全因死亡率。结果:共2473例患者(年龄65±12岁;74%男性)接受PCI,其中53%为股骨通路,47%为桡骨通路。大多数患者(82%)患有单支冠状动脉疾病,临床表现不均匀(21.8% st段抬高型心肌梗死,25.4%非st段抬高型心肌梗死,4.9%不稳定型心绞痛,33.8%稳定型心绞痛,3.4%不典型胸痛,10.7%其他PCI指征)。对于股骨通路,第三阶段(ACT≥275)的患者在30天的全因死亡率明显更高(5.3% vs 2.7% vs 0.9%;P < 0.001), 6个月(6.3% vs 4.0% vs 2.0%;P = .007)和1年(9.0% vs 6.0% vs 2.7%;P < 0.001),分别高于第二分位(ACT 228 ~ 275)和第一分位(ACT≤228)。一项30天的里程碑式分析显示,30天以上的全因死亡率没有差异(3.9% vs 3.4% vs 1.8%;P = .176)。最高不育组出血并发症增加(12.8% vs 9.8% vs 7.5%;P = 0.034)和更高的血液制品需求(10.4% vs 6.7% vs 5.4%;P = .014)。各组间缺血性主要不良心血管事件,特别是围手术期心肌梗死或卒中发生率无差异。桡骨通路患者的临床结果与ACT峰值没有差异。结论:经股通道PCI术中ACT升高与PCI术后30天死亡率、出血并发症和血液制品需求增加相关。
Peak Procedural ACT Is Associated With All-Cause Mortality After Femoral Access PCI.
Background: A minimum threshold activated clotting time (ACT) to guide heparin dosing during percutaneous coronary intervention (PCI) is associated with lower ischemic complications. However, data are variable regarding the risk of high ACT levels. The aim of this study was to assess the impact of peak procedural ACT on complications and mortality for transfemoral and transradial access PCI.
Methods: The UC San Diego Health National Cardiovascular Data Registry CathPCI Registry was used to obtain data on patients who underwent native vessel PCI from January 2007 to September 2022. Coronary artery bypass graft patients and those who received bivalirudin were excluded. Complications and all-cause mortality at 30 days and 1-year post-PCI were assessed by ACT tertile.
Results: A total of 2473 patients (age 65 ± 12 years; 74% male) undergoing PCI with 53% femoral and 47% radial access were included. The majority (82%) had 1-vessel coronary artery disease with heterogeneous clinical presentations (21.8% ST-elevation myocardial infarction, 25.4% non-ST-elevation myocardial infarction, 4.9% unstable angina, 33.8% stable angina, 3.4% atypical chest pain, 10.7% other indication for PCI). With femoral access, patients in the third tertile (ACT ≥ 275) had significantly higher all-cause mortality at 30 days (5.3% vs 2.7% vs 0.9%; P < .001), 6 months (6.3% vs 4.0% vs 2.0%; P = .007), and 1 year (9.0% vs 6.0% vs 2.7%; P < .001) compared to the second (ACT 228-275) and first tertile (ACT ≤ 228), respectively. A 30-day landmark analysis revealed that there was no difference in all-cause mortality beyond 30 days (3.9% vs 3.4% vs 1.8%; P = .176). There were increased bleeding complications in the highest tertile (12.8% vs 9.8% vs 7.5%; P = .034) and a higher need for blood products (10.4% vs 6.7% vs 5.4%; P = .014). There was no difference in ischemic major adverse cardiovascular events specifically periprocedural myocardial infarction or stroke between tertiles. There was no difference in clinical outcomes by peak ACT for patients who had radial access.
Conclusions: Higher ACT with transfemoral access PCI was associated with increased 30-day mortality, bleeding complications, and need for blood products post-PCI.